Paraphilias: a double-blind crossover comparison of clomipramine versus desipramine. 1992

M J Kruesi, and S Fine, and L Valladares, and R A Phillips, and J L Rapoport
Child Psychiatry Branch, National Institute of Mental Health, Bethesda, Maryland 20892.

A relationship has been suggested between clinical presentation of paraphilias and obsessive-compulsive disorder (OCD) with respect to the unwanted repetitive nature and insight into the irrationality of the paraphiliac behavior. This has led to speculation that paraphiliac disorders might belong to an "obsessive compulsive spectrum." To address this issue, and because of the striking selective benefit of serotonin reuptake blocking antidepressants (such as clomipramine) in the treatment of OCD, 15 paraphiliacs entered a double-blind crossover comparison of clomipramine vs. desipramine preceded by a 2-week single-blind placebo period. Four subjects responded to placebo and were dropped from the study. Three others failed to complete the study. Although the study is limited by the small number of patients and the heterogeneity of the paraphilias, the observed benefit from both tricyclics (over the initial placebo) encourages further study. For the 8 subjects completing the protocol, there was no preferential response to the more specific serotonin reuptake inhibitor suggesting a difference in underlying pathophysiology between paraphilia and OCD.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D010262 Paraphilic Disorders Disorders that include recurrent, intense sexually arousing fantasies, sexual urges, or behaviors generally involving nonhuman objects, suffering of oneself or partners, or children or other nonconsenting partners. (from DSM-V) Paraphilias,Sex Deviations,Deviation, Sex,Deviations, Sex,Disorder, Paraphilic,Disorders, Paraphilic,Paraphilia,Paraphilic Disorder,Sex Deviation
D002997 Clomipramine A tricyclic antidepressant similar to IMIPRAMINE that selectively inhibits the uptake of serotonin in the brain. It is readily absorbed from the gastrointestinal tract and demethylated in the liver to form its primary active metabolite, desmethylclomipramine. Chlorimipramine,Anafranil,Chlomipramine,Clomipramine Hydrochloride,Clomipramine Maleate (1:1),Clomipramine Monohydrochloride,Hydiphen,Hydrochloride, Clomipramine,Monohydrochloride, Clomipramine
D003891 Desipramine A tricyclic dibenzazepine compound that potentiates neurotransmission. Desipramine selectively blocks reuptake of norepinephrine from the neural synapse, and also appears to impair serotonin transport. This compound also possesses minor anticholinergic activity, through its affinity to muscarinic receptors. Desmethylimipramine,Apo-Desipramine,Demethylimipramine,Desipramine Hydrochloride,Norpramin,Novo-Desipramine,Nu-Desipramine,PMS-Desipramine,Pertofran,Pertofrane,Pertrofran,Petylyl,Ratio-Desipramine,Apo Desipramine,Hydrochloride, Desipramine,Novo Desipramine,Nu Desipramine,PMS Desipramine,Ratio Desipramine
D004311 Double-Blind Method A method of studying a drug or procedure in which both the subjects and investigators are kept unaware of who is actually getting which specific treatment. Double-Masked Study,Double-Blind Study,Double-Masked Method,Double Blind Method,Double Blind Study,Double Masked Method,Double Masked Study,Double-Blind Methods,Double-Blind Studies,Double-Masked Methods,Double-Masked Studies,Method, Double-Blind,Method, Double-Masked,Methods, Double-Blind,Methods, Double-Masked,Studies, Double-Blind,Studies, Double-Masked,Study, Double-Blind,Study, Double-Masked
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D016896 Treatment Outcome Evaluation undertaken to assess the results or consequences of management and procedures used in combating disease in order to determine the efficacy, effectiveness, safety, and practicability of these interventions in individual cases or series. Rehabilitation Outcome,Treatment Effectiveness,Clinical Effectiveness,Clinical Efficacy,Patient-Relevant Outcome,Treatment Efficacy,Effectiveness, Clinical,Effectiveness, Treatment,Efficacy, Clinical,Efficacy, Treatment,Outcome, Patient-Relevant,Outcome, Rehabilitation,Outcome, Treatment,Outcomes, Patient-Relevant,Patient Relevant Outcome,Patient-Relevant Outcomes

Related Publications

M J Kruesi, and S Fine, and L Valladares, and R A Phillips, and J L Rapoport
March 1999, European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology,
M J Kruesi, and S Fine, and L Valladares, and R A Phillips, and J L Rapoport
December 1989, Archives of general psychiatry,
M J Kruesi, and S Fine, and L Valladares, and R A Phillips, and J L Rapoport
June 1995, The Journal of clinical psychiatry,
M J Kruesi, and S Fine, and L Valladares, and R A Phillips, and J L Rapoport
September 1991, Archives of general psychiatry,
M J Kruesi, and S Fine, and L Valladares, and R A Phillips, and J L Rapoport
August 1989, The New England journal of medicine,
M J Kruesi, and S Fine, and L Valladares, and R A Phillips, and J L Rapoport
June 1993, Archives of general psychiatry,
M J Kruesi, and S Fine, and L Valladares, and R A Phillips, and J L Rapoport
April 1996, Journal of clinical psychopharmacology,
M J Kruesi, and S Fine, and L Valladares, and R A Phillips, and J L Rapoport
March 1988, Canadian journal of psychiatry. Revue canadienne de psychiatrie,
M J Kruesi, and S Fine, and L Valladares, and R A Phillips, and J L Rapoport
January 1988, Psychopharmacology bulletin,
M J Kruesi, and S Fine, and L Valladares, and R A Phillips, and J L Rapoport
August 2001, Journal of clinical psychopharmacology,
Copied contents to your clipboard!